It has been a brutal year for cannabis investors. Heading into 2020, cannabis investors are now weighing whether to cut their losses or buy the dip in a bet on a rebound ahead.
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Alan Brochstein, author of the 420 Investor and founding partner of New Cannabis Ventures, recently discussed his outlook for cannabis stocks on Benzinga’s daily PreMarket Prep podcast.” data-reactid=”19″>Alan Brochstein, author of the 420 Investor and founding partner of New Cannabis Ventures, recently discussed his outlook for cannabis stocks on Benzinga’s daily PreMarket Prep podcast.
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="While leading cannabis stocks like Canopy Growth Corp (NYSE: CGC) appear to have bottomed in November, many of the lower-tier names have continued lower into the end of the year, dragging down the group as a whole, Brochstein said.” data-reactid=”20″>While leading cannabis stocks like Canopy Growth Corp (NYSE: CGC) appear to have bottomed in November, many of the lower-tier names have continued lower into the end of the year, dragging down the group as a whole, Brochstein said.
“I think the issue may be a little bit of tax loss selling. The rest of the market is having a really nice year, and we’re having a really crappy year,” he said.
Brochstein’s Longer-Term Bull Thesis
Despite the bumps in the road, Brochstein remains bullish for the long haul.
“I think this is going to be a great story as it plays out over multiple years, but there’s always potholes and this year was full of them,” he said.
Brochstein said supply constraints in Canada, lackluster rollouts in California, the vaping crisis and a cannabis capital crunch all combined to create a perfect storm for cannabis stocks in 2019.
“My outlook for next year is not a roaring bull, although I could be surprised I suppose. The downturn we’re going through is really healthy for the industry.”
A surplus exists of public cannabis companies, and the market downturn will eliminate many of the worst companies and allow others to consolidate, Brochstein said.
The 420 Investor’s Stock Picks
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="GLJ Research analyst Gordon Johnson recently set a zero price target for Aurora Cannabis Inc (NYSE: ACB) and said the company is running out of cash.” data-reactid=”29″>GLJ Research analyst Gordon Johnson recently set a zero price target for Aurora Cannabis Inc (NYSE: ACB) and said the company is running out of cash.
Brochstein said the company is taking on its cash problems aggressively.
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Aurora and Tilray Inc (NASDAQ: TLRY) are the weakest among the top-tier cannabis stocks in terms of funding given that Canopy and Cronos Group Inc (NASDAQ: CRON) have large strategic investors, he said.” data-reactid=”31″>Aurora and Tilray Inc (NASDAQ: TLRY) are the weakest among the top-tier cannabis stocks in terms of funding given that Canopy and Cronos Group Inc (NASDAQ: CRON) have large strategic investors, he said.
“Both these companies need to raise cash to fund their U.S. operations. So in terms of running out of cash, the reality is they’re not going to run out of cash,” he said. “They have an ATM, and they’ll keep hitting it … I’m more concerned that they may have to slow down in the United States.”
Looking ahead to 2020, Brochstein said he expects the cannabis stocks with the best balance sheets to continue to outperform.
“We’ve already seen a few bankruptcies, we’ve seen some companies raise capital at atrocious levels — and there are some companies out there that are going to really struggle next year, and I think this is going to be to the benefit of the well-capitalized companies that are proving out their business models.”
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Brochstein also weighed in on a couple of other cannabis stocks: Cresco Labs Inc (OTC: CRLBF), Green Thumb Industries Inc (OTC: GTBIF).” data-reactid=”35″>Brochstein also weighed in on a couple of other cannabis stocks: Cresco Labs Inc (OTC: CRLBF), Green Thumb Industries Inc (OTC: GTBIF).
“These are the two companies that are best-positioned in Illinois, which is legalizing in less than two weeks … you have a headline catalyst that I think could be positive.”
Other Experts Weigh In
Kase Capital Management hedge fund manager Whitney Tilson also weighed in on cannabis stocks last week, saying that the massive sell-off has likely started creating buying opportunities.
“Unlike bitcoin and other cryptocurrencies — which are nothing but a techno-libertarian pump-and-dump scheme, so there is no price at which I would recommend them — the cannabis sector is very real and will grow enormously from here. Thus, my instinct is that investment opportunities are beginning to emerge in the sector,” Tilson said.
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Stansberry Research analyst Tom Carroll also said last week that market dynamics alone may drive cannabis stocks higher in early 2020.” data-reactid=”40″>Stansberry Research analyst Tom Carroll also said last week that market dynamics alone may drive cannabis stocks higher in early 2020.
“Given that almost everyone is underwater on their investments in this sector, there’s likely a lot of heavy selling to capture tax losses, which is pressuring stocks this month. But people — especially individuals — want to own these things, so they will buy back in January,” Carroll said.
Benzinga’s Take
The long-term outlook for the cannabis business remains bright, but determining the timing of regulatory changes and predicting the ultimate market share winners is extremely difficult at this point. Cannabis investors should be prepared for more unpredictability and volatility in 2020.
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Do you agree with this take? Email [email protected] with your thoughts.” data-reactid=”44″>Do you agree with this take? Email [email protected] with your thoughts.
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Related Links:” data-reactid=”45″>Related Links:
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Analyst On Hexo Earnings: ‘We Had Expected Worse’ ” data-reactid=”46″>Analyst On Hexo Earnings: ‘We Had Expected Worse’
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="The SAFE Act Could Be 2020’s Biggest Cannabis Catalyst” data-reactid=”47″>The SAFE Act Could Be 2020’s Biggest Cannabis Catalyst
Latest Ratings for ACB
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 2019 | Maintains | Sell | ||
| Nov 2019 | Maintains | Sell | ||
| Nov 2019 | Upgrades | Neutral | Overweight |
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="View More Analyst Ratings for ACB
View the Latest Analyst Ratings” data-reactid=”51″>View More Analyst Ratings for ACB
View the Latest Analyst Ratings
0
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="See more from Benzinga” data-reactid=”53″>See more from Benzinga
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.” data-reactid=”58″>© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Add Comment